The Australian share market traditionally provides investors with an average return of approximately 10% per annum.
While this is good, investors don't have to settle for average. Not when there are ASX 200 shares out there that analysts believe could generate significantly greater returns over the next 12 months.
With that in mind, let's now take a closer look at two ASX 200 shares that analysts believe could rise between 50% and 80% between now and this time next year. They are as follows:
Image source: Getty Images
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix Pharmaceuticals could be an ASX 200 share with the potential to deliver huge returns for investors.
It is a biotechnology company that specialises in molecular imaging and targeted radiation therapies. This is a new frontier in cancer diagnosis and treatment that combines precision medicine with powerful therapeutic technology.
Its flagship product is Illuccix, which is already approved by regulators and generating strong sales in the US for prostate cancer imaging.
But it isn't stopping there. This ASX 200 share is advancing a deep pipeline of new radiopharmaceutical candidates targeting kidney, brain, and other cancers. And with each of these having the potential to open multi-billion-dollar global markets, Telix certainly has a long growth runway if everything goes to plan.
Bell Potter remains very positive on Telix. It has a buy rating and $23.00 price target on its shares, which implies potential upside of greater than 50% from current levels.
WiseTech Global Ltd (ASX: WTC)
Another ASX 200 share that could be undervalued is logistics solutions technology company WiseTech Global.
Its CargoWise software platform supports global supply chains, helping major freight forwarders and logistics companies manage their operations across multiple countries and modes of transport.
Its recurring revenue has proven incredibly sticky in recent years. Once a customer integrates CargoWise, switching providers is complex and costly.
In addition, WiseTech Global continues to expand both organically and through acquisitions, strengthening its product suite and deepening its global reach.
And with profit margins few rivals can match and a strong balance sheet to fund future growth, analysts at Morgans believe that it deserves a premium valuation.
For example, the broker currently has a buy rating and $127.50 price target on its shares. This suggests that upside of 80% is possible for investors over the next 12 months from where they trade today.
